FDA Clearance Tracker · P220023-S002
ReCor Paradise® Ultrasound Renal Denervation System
Last checked: Nov 20, 2026Latest source record: Feb 5, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Feb 5, 2024
Approved
Time to decision
59 days
Received Dec 8, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P220023-S002
- Device name
- ReCor Paradise® Ultrasound Renal Denervation System
- Applicant
- Recor Medical, Inc.
- Applicant location
- Palo Alto, CA
- Received
- Dec 8, 2023
- Decided
- Feb 5, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P220023
Device type
- Device type
- Ablation catheter, renal denervation (QYI)
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval of the protocol for the US arm of the Global Paradise System Post Approval Study
Source documents
Other decisions for Recor Medical, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Paradise® Ultrasound Renal Denervation SystemBreakthroughPMA
P220023 · Decided Nov 7, 2023 · 378 days after receipt
Device type: Ablation catheter, renal denervation (QYI) · Cardiology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.